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Successful management of uric acid nephrolithiasis with potassium
citrate. Eighteen patients with uric acid nephrolithiasis (six with uric
acid stones alone and 12 with both uric acid and calcium stones)
underwent long—term treatment (I to 5.33 years, mean of 2.78 years)
with potassium citrate (30 to 80 mEq/day, usually 60 mEq/day). Urinary
pH increased from low (5.30 0.31 so) to normal (6.19 to 6.46) during
treatment. Urinary content of undissociated uric acid, which was high
to begin with at 204 82 mg/day, decreased to the normal range (64 to
108 mg/day) following treatment. Urinary citrate rose from 503 .L 225
mg/day to 852 to 998 mg/day. Urinary saturation of calcium oxalate
significantly declined with potassium citrate treatment. New stone
formation rate declined from 1.20 1.68 stones/year to 0.01 0.04
stones/year (P < 0.001 by ehi square). Remission was experienced in
94.4% of patients, and the group stone formation rate declined by
99.2%. Detailed case reports were obtained in five patients showing
different responses between sodium alkali and potassium alkali treat-
ment. All five patients had persistently low urinary pH (typically < 5.5)
and normouricosuria, and four had hyperuricemia. Before treatment,
they had stones surgically removed or spontaneously passed, which
were pure uric acid in composition. When sodium alkali was give (as
bicarbonate or citrate, 60 to 118 mEq/day), new stone formation
continued in four patients, and a radiolucent (uric acid) calculus become
"calcified" in the remaining patient. The stone analysis disclosed
calcium oxalate in five patients and calcium phosphate in three patients.
When potassium citrate (in four cases) or potassium bicarbonate (in one
case) was offered instead over 1 to 3.5 years (at a dosage of 60 to 80
mEq/day), no new stones were formed. The results provide physiolog-
ical and physicochemical rationale, as well as therapeutic efficacy for
potassium citrate treatment in the management of uric acid lithiasis
presenting with/without calcium stones.
Renal stones of uric acid form when the urinary concentra-
tion of undissociated uric acid exceeds the solubility limit. The
dissociation of uric acid is pH-dependent with increasing
amounts of undissocjated uric acid or reduced uric acid solubil-
ity at lower pH [11. Thus, unusually acid urinary environment,
wilh pH less than the dissociation constant of uric acid or 5.5,
is characteristically encountered in patients with uric acid
lithiasis [2). Causes of low urinary pH and uric acid stone
formation include gouty diathesis, chronic diarrheal syndrome
and excessive intake of meat products of high purine and acid
ash content.
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For the control of uric acid lithiasis, it has therefore been
customary to provide alkali therapy to increase urinary pH in
order to reduce the concentration of undissociated uric acid.
Unfortunately, alkali therapy may sometimes cause complica-
tion of calcium stones 13, 4]. There is some experimental and
clinical evidence that sodium alkali may exaggerate, whereas
potassium alkali may alleviate this complication [5].
In our earlier study in patients with uric acid lithiasis [5],
sodium citrate treatment increased urinary pH and dissociation
of phosphate without decreasing urinary calcium, thereby rais-
ing the saturation of calcium phosphate. Moreover, urinary
saturation of monosodium urate rose owing to the sodium
delivered with the alkali. Thus, the inhibitor activity against the
spontaneous precipitation of calcium oxalate was sometimes
decreased despite the increased excretion of citrate, possibly
because of the monosodium urate—induced crystallization of
calcium oxalate [6]. Thus, while it may prevent uric acid stone
formation, sodium alkali may potentially cause or exaggerate
calcium nephrolithiasis. This conclusion is supported by reports
of calcium phosphate nephrolithiasis with an overaggressive
alkali therapy [3, 4], and occurrence of mixed uric acid—calcium
stones [7]. An "alkaline tide" from ingestion of an alkaline ash
diet, especially in the setting of a high sodium intake, could
potentially account for the development of mixed stones, since
it would increase urinary saturation of monosodium urate and
promote urate—indiiced crystallization of calcium oxalate.
Our preliminary study indicated that potassium citrate may
be devoid of the complication of sodium alkali. Thus, potassium
citrate therapy reduced urinary calcium, increased urinary pH
and citrate, reduced urinary saturation of calcium oxalate
without affecting that of calcium phosphate and monosodium
orate, and enhanced inhibitor activity against crystallization of
calcium oxalate [8], and inhibited calcium stone formation in
patients with uric acid lithiasis [91.
This report provides additional evidence for the apparent
advantage and efficacy of potassium citrate in the management
of uric acid nephrolithiasis. It represents biochemical and
clinical results of our long—term clinical trial with potassium
citrate in 18 patients with uric acid lithiasis, 12 of whom also
had calcium stones. In five patients with uric acid lithiasis,
detailed case reports are provided showing that complication of
calcium nephrolithiasis occurring during sodium alkali therapy
was absent on potassium alkali treatment.
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Table 1. Clinical and biochemical data on initial presentation before potasslum citrate treatment'
Groups
Uric acid Uric acid Potassium Potassium
stones + Ca citrate citrate + Combined
alone stones alone other group
No. patients 6 12 II 7 18
Men/Women, no. 4/2 10/2 8/3 6/I 15/3
Age, yr 45 19 50 II 52 12 42 15 48 14
Clinical Gout, no. 0 I 0 1
Hyperuricemia, no. 3 1 0 4 4
Hyperuricosuria, no. 4 1 3 2 5
Family Hx Gout I 2 2 1 3
Serum
Uric Acid, mg/dl 7.8 1.8 7.2 1.6 6.9 0.9 8.3 2.3 7.4 1.7
Urinary
pH 5.38 0.47 5.29 0.20 5,25 0.25 5.36 0.39 5.30 0.31
Ca, mg/day 128 49 183 61 165 54 164 76 164 62
Uric acid, mg/day 613 284 405 171 486 175 456 313 474 230
Citrate, mg/day 470 170 520 253 588 202 371 206* 503 225
Oxalate, mg/day 29.8 4.6 28.0 9.8 30.5 6.8 25.7 10.2 28.6 8.3
P, mg/day 811 238 855 214 798 209 907 227 840 216
Sodium, mEq/day 144 52 117 47 136 48 110 49 126 49
Potassium, mEq/day 50 17 46 23 49 22 45 20 46 21
a Hyperuricemia represented serum uric acid exceeding 8 mg/dl, and hyperuricosuria was rigidly defined as urinary uric acid exceeding 600 mg/
day. Values are presented as mean SD. Significant difference between potassium citrate alone vs. potassium citrate plus other treatment is shown
by * for P < 0.05 (using Student's 1-test).
Methods
Experimental subjects
Case reports. Detailed case reports were obtained in five
patients (three men and two women), ranging in ages from 34 to
59 years at the onset of stone disease. All have evidence of uric
acid lithiasis on stone analysis. Four had hyperuricemia and one
had gouty arthritis. Urinary pH was <5.5 in all patients. Before
referral to us, they were treated with sodium alkali (sodium
citrate or sodium bicarbonate) for a period of 0.2 to three years.
On this treatment, they formed calcareous stones (calcium
oxalate alone or with calcium phosphate). We offered potas-
sium alkali therapy instead. In three patients (Cases 1, 2 and 5),
response to treatment was included in the long—term clinical
trial. In the remaining two patients (Cases 3 and 4), the
follow—up evaluation was not sufficiently detailed for inclusion
in the long—term clinical trial.
Long—term clinical trial. Eighteen adult patients with uric
acid lithiasis participated in the study after an informed written
consent was obtained. Six patients formed only uric acid
stones, and the remaining 12 patients formed mixed stones
containing both uric acid and calcium salts (predominantly
calcium oxalate), or formed both uric acid stones (without
calcium salts) and calcium stones (without uric acid) on sepa-
rate occasions.
Eleven of IS patients were later allocated to receive potas-
sium citrate alone. None of the 11 patients had clinical gout or
hyperuricemia, but three had hyperuricosuria. The remaining
seven patients received potassium citrate with other medical
treatment. Six took allopurinol because of hyperuricemia and
gouty arthritis (in one), asymptomatic hyperuricemia (in three),
or hyperuricosuria (in two). The remaining patient received
hydrochlorothiazide because of unclassified hypercalciuria.
In the combined group of 18 patients (six with uric acid alone
and 12 with uric acid plus calcium stones, or 11 taking potas-
sium citrate alone and seven taking potassium citrate with
allopurinol or thiazide), one had gouty arthritis, four
hyperuricemia and five had hyperuricosuria. Three had a family
history of gout. No one gave a history of gout. No one gave a
history of intestinal disease, chronic diarrhea or hematological
disorders. All patients denied taking any medication on a
constant basis. Diet history did not disclose any remarkable
difference from that provided by patients with absorptive or
renal hypercalciurias who formed calcium stones alone.
Long—terminal biochemical data in patients undergoing
long—term trial, l'ahle I. Compared to values in our normal
subjects without stones, serum uric acid was marginally ele-
vated in patients with uric acid stones alone and in patients who
later received both potassium citrate and allopurinol or thiazide
(normal < 8 mg/dl). Urinary pH in all groups was significantly
lower than the value in control subjects of 5.90 0.41 (P <
0.001). Urinary citrate compared to the value in the control
subjects was low only in the group receiving potassium citrate
plus other treatment (P < 0,Ol)(normal> 320 mg/day) [10]. The
remaining urinary parameters were not significantly different
from values in control subjects. All patients had normal values
for serum calcium, phosphorus, sodium, potassium, chloride
and carbon dioxide (not shown here); their endogenous creati-
nine clearance exceeded 65 mI/mm.
When values in patients with uric acid stones alone were
compared with those of patients with uric acid plus calcium
stones, the only difference noted was a higher urinary uric acid
in the former group (P < 0.05). When values in patients
receiving potassium citrate alone were compared with those of
patients receiving combined treatment, the only significant
difference was the lower citrate excretion in the latter group (P
< 0.05).
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Study protocol (ion g—terrn clinical trial)
Before institution of potassium citrate treatment, two
24—hour urine samples were obtained while patients were
maintained on their customary diet and fluid intake at home.
The samples were analyzed for total volume, pH, calcium,
citrate, uric acid, oxalate, sodium, potassium and phosphorus.
Moreover, the relative saturation ratio of calcium oxalate ill],
permissible increment in oxalate [1 21, and undissociated uric
acid were calculated. For each test, the mean of two determi-
nations from each patient was taken as the prc-treatment value.
The patients were followed in an outpatient setting every four
months during treatment, at which time a 24—hour urine sample
was collected for the same tests as before treatment. At each
visit, a careful history was obtained for new stone formation
[13]. Abdominal roentgenologic examination was obtained cv-
cry one to two years, more often if necessary, in order to
document new stone formation (spontaneous passage in the
absence ol pre-existing stones, stone passage occurring without
change in number of stones, appearances of new stones on
x-ray films).
For the three years immediately preceding institution of
treatment, a careful retrospective history was taken from pa-
tients for spontaneous passage or surgical removal of stones.
The history was corroborated by medical records of referring
physicians and available x-rays of the urinary tract.
All patients received potassium citrate at a dosage of 30 to 80
mEq/day in three—to—four divided doses (usually 60 mEq/day)
(Urocit, Mission Pharmacal Co., slow—release tablet, or liquid
preparation dissolved in distilled water). Among six patients
who took concurrent medication, the dosage of allopurinol was
lOt) mg three timcs/day (in five patients) and that of
hydrochlorothiazide was 50 mg/day (in one patient). These
treatments were begun concurrently with potassium citrate.
Analytical methods
Urinary calcium was analyzed by atomic absorption spec-
trophotometry, citrate by the enzymatic method using
Boehringer—Mannheim kit (Boehringer Ingelheim Ltd., Ridge-
field, Connecticut, USA), and uric aid by the unease method.
Oxalate was determined by the colorimetric technique of
Hodgkinson and Williams [14], and sodium and potassium by
flame photometry. The relative saturation ratio (RSR) of cal-
cium oxalate represented the product of ionic activities of
calcium and oxalate of the original urine sample (calculated by
the computer program of Finlayson [15]) divided by the ther-
modynamic soluhility product of calcium oxalate [1]. A value of
1 indicated saturation, >1 supersaturation, and <1 undersatura-
tion. Undissociated uric acid in individual urine sample was
calculated by the computer program of Finlayson [151. The
concentration of undissociated uric acid at saturation in human
urine has been shown to be 96 2 mg/liter at 37°C [8]. The
permissible increment in oxalate was determined by adding
soluble oxalate to whole urine until spontaneous precipitation
of calcium oxalate occurred [12]. It represented the minimum
amount of additional oxalate that could bc added to urine before
eliciting spontaneous precipitation of calcium oxalate at three
hours.
The effect of potassium citrate treatment on urinary biochem-
istry and on new stone formation was assessed in the combined
group of 18 patients, since qualitatively similar changes were
obtained in different groups. Significant difference in urinary
values between pre-treatment and post-treatment period s was
assessed by repeated measures analysis of variance 1161. The
calculation was not performed beyond 24 months of treatment
because the limited number of observations precluded accurate
statistical analysis. The significant difference to individual stone
formation rate produced by potassium citrate treatment was
calculated by the Wilcoxon's t-test. Significance of the number
of stones actually formed during the treatment versus predicted
was determined by chi square test. Values are presented as
mean SD.
Case histories
Case 1. The stone disease for this white man began at 34
years of age when he passed a uric acid stone. He was begun on
treatment with sodium citrate 30 mEq twice/day, orally. Uri-
nary pH of 6.5 was reported on this treatment.
During the succeeding 18 months (while on sodium alkali
therapy), he passed 18 stones spontaneously. At II months of
treatment, he underwent left pyelolithotomy for removal of four
radiopaque stones. The stone analysis disclosed the presence of
calcium oxalate.
At 36 years of age, he was referred to us for an outpatient
evaluation [2], after alkali treatment had been stopped for two
weeks. He denied history of gouty arthritis or intestinal disease.
He had high serum uric acid of 8.6 mg/dl, normal urinary uric
acid of 157 to 588 mg/day and low urinary pH of 5.22 to 5.33.
Urinary calcium was normal at 100 to 176 mg/day, as was
urinary oxalate at 15 mg/day. Abdominal roentgenogram dis-
closed the presence of two radiopaque calculi (0.5 x 0.5 cm) on
the right kidney.
Immediately following evaluation, he was begun on treatment
with potassium citrate 20 mEq three times/day, orally. In this
patient as well as remaining patients to be described, a moder-
ate sodium intake was imposed (approximately 100 mEq/day).
During the succeeding 3.7 years of treatment, his urinary citrate
was maintained at 692 to 1088 mg/day, pH 6.24 to 6.91, and uric
acid 397 to 644 mg/day. Although he still had pre-existing
calculi, he had not passed any stones or required surgery.
Case 2. The onset of stone disease for this white woman was
at 51 years of age, when she passed two stones (100% uric acid).
Upon passage of another stone six months later, she was begun
on treatment with alkali containing 84 mEq of sodium bicarbon-
ate, 9 mEq of sodium citrate and 50 mEq of citric acid/day (in
thrice daily schedule). Urinary p11 of 6.8 was reported during
the treatment, The plain film of the abdomen did not show
existing stones when the treatment was started.
During three years of sodium alkali treatment she passed five
stones. The analysis of the stone passed during the third year of
therapy revealed that the stone was composed of 65% calcium
oxalatc and 35% calcium phosphate (apatite).
At 55 years of age, she was referred to us for evaluation two
weeks after sodium alkali treatment was stopped. She did not
suffer from gouty arthritis or intestinal disease. She had
hypcruriceniia of 8 mg/dl, low urinary pH of 4.82 to 4.91, and
normal urinary uric acid of 180 to 378 mg/day. Urinary calcium
ranged from 156 to 350 mg/day (normal to high), urinary oxalate
was mildly elevated at 45 mg/day, and urinary citrate was
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normal at 735 mg/day. She had two radiopaque calculi (0.5 x
0.5 cm), one on each kidney.
Immediately following evaluation, potassium citrate therapy
(20 mEq three times/day) alone was begun. During the succeed-
ing 36 months of treatment, she did not pass any stones, but
required right ureterolithotomy for the obstruction caused by an
existing stone. She continued to have a residual calculus
unchanged in size. Urinary citrate had been kept at 493 to 875
mg/day, urinary pH 6.56 to 6.87, and urinary uric acid 203 to 523
mg/day.
Case 3. At 57 years of age, this white woman underwent
removal of left ureteral stone via basket. The analysis of the
stone revealed uric acid. One year later, she passed three small
stones and required another basket extraction for a left ureteral
calculus. All stones were composed of uric acid. Serum uric
acid was high at 9.7 mg/dl. She was begun on treatment with
allopurinol 100 mg three times/day.
At 59 years of age (after nine months of allopurinol treat-
ment), she was hospitalized with renal colic due to a radiolucent
stone (1.2 x 0.5 cm) in the right uretero-pelvic junction. Serum
uric acid had decreased to 4.3 mg/dl. A two—month course of
treatment with sodium bicarbonate (59 mEq twice/day) was
attempted to dissolve the stone, but failed, The stone, removed
by pyelolithotomy, had "superficial and intermixed deposits of
random oriented to columnar monoclinic needles of calcium
oxalate monohydrate". Urinary pH of 7.1 was reported during
sodium alkali therapy.
Evaluation (six weeks after alkali therapy was stopped)
disclosed that she had hyperuricemia of 8.8 mg/dl, low urinary
pH of 5.22 to 5.39 and normal urinary uric acid of 477 mg/day.
Urinary calcium was normal at 114 to 184 mg/day, urinary
citrate was low at 280 mg/day and urinary oxalate was normal at
23 mg/day. Abdominal roentgenogram disclosed several small
radiopaque renal calculi on the right kidney. Although she did
not have intestinal disease, she gave a history of intermittent
gouty arthritis involving the right toe.
She was instructed to take allopurinol 100 mg three times/day
and potassium citrate 20 mEq four times/day orally. At four
months of treatment, urinary citrate was 583 mg/day, urinary
pH 6.74, and uric acid 354 mg/day. Although further follow-up
evaluation by us had not been possible, she had not passed any
stones or required surgery during one year of treatment.
Case 4. This white man required right pyelolithotomy for a
uric acid stone at 60 years of age. Two years later, he had a left
pyelolithotomy for a uric acid stone. At that time, he was begun
on treatment with allopurinol 100 mg three times/day and
sodium citrate 30 mEq twice/day. He continued to pass stones
on this treatment (five during one year of treatment, 10 during
two years before treatment).
He was then referred to us for evaluation (at 63 years of age)
one month after sodium alkali treatment was stopped. He had
low urinary pH of 5.38 to 5.58. However, he had normal values
for serum uric acid at 5.6 mg/dl, urinary uric acid at 483 to 504
mg/day, calcium at 106 to 205 mg/day and oxalate at 23 mg/day.
Although he did not have any pre-existing stones on roentgen-
ologic examination, the analysis of two stones passed during the
period of sodium alkali therapy showed that the calculi were
composed of calcium oxalate and calcium apatite. He denied
suffering from gout or intestinal disease.
Immediately following evaluation, he was begun on treatment
with potassium bicarbonate 20 mEq twice to three times/day
and allopurinol 100 mg three times/day. The follow-up exami-
nation one year later disclosed urinary pH of 5.97 and uric acid
of 380 mg/day. He had not passed any stones or required
surgical removal of stones for 18 months.
Case 5. This white man began to pass stones at 31 years of
age. During the succeeding 32 years, he passed more than 50
stones spontaneously, 10 of them during the last three years. At
60 years of age, he required left ureterolithotomy. The stone
analysis disclosed 100% uric acid. No treatment was given.
When he was evaluated by us at 63 years of age, he had
hyperuricemia of 9.3 mg/dl, low urinary pH of 5.37, and normal
urinary acid of 290 to 522 mg/day. He had normal values for
urinary calcium of 174 mg/day, oxalate of 29 mg/day and citrate
of 454 mg/day. He denied history of gouty arthritis of intestinal
disease.
Following evaluation, he was begun on treatment with so-
dium bicarbonate 74 mEq/day, and potassium bicarbonate 9
mEq/day in three divided doses. Urinary pH increased to 6.30
to 6.90. He passed a stone at eight months of treatment. The
analysis of the stone disclosed that the uric acid core was
covered with a shell composed of 90% calcium oxalate and 10%
calcium apatite. At 66 years of age (after taking mixed
sodium—potassium alkali for three years), abdominal roentgen-
ogram disclosed a radiopaque stone in each kidney. During the
above treatment, he passed three stones spontaneously.
At 66 years of age, the treatment with sodium bicarbonate—
potassium bicarbonate was stopped and substituted with potas-
sium citrate at a dose of 20 mEq three times/day orally. During
3.5 years of potassium citrate treatment, he continued to have
two radiopaque calculi, but there was a substantial reduction in
stone mass on the left kidney. He had not required surgical
removal of stones, but passed one stone (probably pre-exis-
ting). Urinary citrate had been maintained at 784 to 1002
mg/day, pH 6.65 to 6.95, and uric acid at 483 to 658 mg/day.
Results
Summary of' case reports
All five patients had documented passage of uric acid stones
before alkali treatment. Alkali was given as sodium citrate (in
cases I and 4), sodium bicarbonate (in case 3), a mixture of
sodium bicarbonate, sodium citrate and citric acid (in case 2),
and as a mixture of sodium bicarbonate and potassium bicar-
bonate (in case 5), for a period ranging from 0.2 to 3 years. The
amount of sodium alkali ranged from 60 to 118 mEq/day.
The stone analysis after alkali therapy showed calcium stones
(calcium oxalate or a mixture of calcium oxalate and calcium
apatite) occurring in toW (cases 1, 2, and 4) or as a shell
overlying a core of uric acid (cases 3 and 5).
The doses of two forms of alkali were equivalent (60 to 118
mEq/day for sodium alkali and 60 to 80 mEq/day for potassium
alkali). During sodium alkali therapy, urinary pH (available in
four patients) ranged from 6.3 to 7.1. During potassium alkali
treatment, urinary pH ranged from 5.97 to 6.91.
During sodium alkali treatment, four patients continued to
form new stones (passed/surgically removed). Case 3 required
surgical removal for a probable uric acid stone which became
coated with calcium salts. The rate of new stone formation
decreased during treatment in Case 5.
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Table 2. Eifect of potassium citrate therapy on urinary biochemistrvU
Duration of
treatment, ma. Pre- 4 8 12 16 20 24
Total volume mi/day 1538 738 2260 1020 2319 799 2245 8522014± 801 2211 513 2100 708
p1-I 5.30 0.31 6.19 0.65* 6.41 0.56* 6.20 0.63* 6.24 0.60* 6.46 0.52* 6.40 059*
Calcium mg/day 165 62 184 99 157 53 167 59 151 50 173 78 167 92
Citrate mg/day 503 225 852 336* 998 334* 904 293* 874 351* 862 185* 947 32I'
Uric acid mg/day 474 230 477 196 690 279 597 203 568 179 585 196 528 148
Oxalate mg/day 28.6 8.3 31,7 8.8 34.7 10.8 35.2 7.6 30.6 6.8 31.0 6.8 32.3 8.2
Sodium mEq/day 126 49 197 77* 210 73* 205 55* 187 64 183 t 45 187 64
Potassium mEq/day 48 21 95 30* 02 42* 102 30* 99 42* 89 31* 95 30'
Phosphorus mg/day 840 216 887 276 888 320 1012 312 1027 361 914 412 884 358
RSR, Ca oxalate 7.38 4.53 5,37 3.59 4.31 2.44* 4.53 2.18* 4.81 2.84* 4.13 2.63* 4.59 3.00*
Permissible increment 37.2 24.2 48.8 24.4 72.8 20.3* 54.5 23.0* 59.2 24,0* 69.2 27.4* 78.4 10.5*
in oxalate mg/liter
Undissociated 204 82 82 74 107 135 100 99 108 112 65 76* 64 69*
uric acid mg/day
U Values are presented as mean SD, For each test, significant difference from pre-trcatment value is given by * for P < 0.05. Abbreviation RSR
is relative saturation ratio.
When potassium citrate/bicarbonate was given over one to
3.5 years, no new stones were passed, and none required
surgical removal of stones.
Long—term clinical trial
Effect of potassium citrate therapy on urinary biochemistry
(Table 2). During potassium citrate treatment in the combined
group of 18 patients, urinary pH rose significantly from the low
value of 5.30 0.31 to normal limits (6.19 to 6.46) (Fig. I).
Urinary uric acid was unaltered by treatment. 'rhe undissoci-
ated uric acid excretion, which was high to begin with at 204
82 mg/day, declined significantly to the normal range (<108
mg/day) during the first 24 months of treatment, owing chiefly to
the rise in urinary pH (Fig. 1).
Urinary citrate, which was low normal before treatment (503
225 mg/day vs. 643 mg/day for normal mean), rose signifi-
cantly to the high normal range when potassium citrate was
provided. There was no significant change in urinary calcium or
oxalate. The urinary saturation of calcium oxalate, assessed by
the relative saturation ratio (RSR) [11], decreased significantly
during most treatment periods. As compared to values in
normal subjects, it was high to begin with, and within normal
limits during treatment [9]. Before potassium citrate treatment,
the permissible increment in oxalate of 37,2 24.2 mg/liter was
significantly lower than that encountered in normal controls of
62.4 25.3 mg/liter [12] (P < 0.001 by Student's t-test). During
most treatment periods, permissible increment in oxalate rose
significantly to the range encountered in normal subjects.
Urinary potassium rose by 36 to 54 mEq/day during treat-
ment. The mean urinary sodium was higher during treatment
than before treatment; this change was significant at 4, 8, 12, 32
and 36 months of Ireatment. The mean urinary total volume was
higher than the pre-treatment value during treatment; the dif-
ference was not significant. The remaining urinary parameters
were not significantly altered by treatment.
In seven patients who received potassium citrate with other
treatment (thiazide or allopurinol), there were no significant
changes in urinary uric acid or in urinary calcium during any of
the treatment periods compared to the pre-treatment period.
Urinary uric acid before treatment was 456 313 mg/day,
comnared to 457 to 680 mg/day during treatment. Urinary
calcium before treatment was 164 76 mg/day, and 125 to 294
mg/day during treatment.
Effect of potassium citrate thei'apy on new stone ,formation
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Fig. 2. Lffect ofpotassium dtrate treatment on new stone formation
Each circle represents new stone formation. Each line indicates study
in a separate patient. Asterisk denotes patients with pre-existing stone
when the treatment with potassium citrate was begun. Bottom seven
patients took potassium citrate concurrently with allopurinol (A) or
thiazide (T).
(Fig. 2). All patients had recurrent stone formation before
potassium citrate was initiated. Although six patients each had
formed only a single stone during three years prior to treatment,
they had previous stone episodes. Seven patients had existing
radiopaque stones when the treatment was begun.
During potassium citrate treatment (one to 5.33 years, mean
of 2.78 1 .34 years), only one stone was formed in the entire
group of 18 patients (Fig. 2). Except for a calcium oxalate stone
passed by one patient, no one showed stone growth, experi-
enced severe renal colic, or required hospitalization or surgery
for removal of stones. The mean stone formation rate declined
significantly from 1.20 1 .68 stones/year before treatment to
0.01 0.04 stones/year during potassium citrate therapy (P <
0.001 by chi square, P < 0.01 by Wilcoxon's t-test). Remission
was experienced in 94.4% of patients, and reduced individual
stone formation rate was encountered in 100% of patients. The
group stone formation rate declined by 99.2% (treatment vs.
pie-treatment).
Discussion
It has long been suggested that alkali treatment may be
complicated by calcium phosphate nephrolithiasis [17—191.
However, this caution may have been based on anecdotal
experience, with few documented publications [20—221. This
study provides detailed case reports of five patients with uric
acid lithiasis who developed calcium stones during treatment
with customary alkali, containing sodium bicarbonate or so-
dium citrate, The formation of calcium oxalate could be ex-
plained by the increased urinary saturation of sodium urate [231
(from the increased delivery of sodium) and consequent sodium
urate—induced crystallization of calcium oxalate [6, 24]. Cal-
cium phosphate lithiasis could be accounted for by increased
dissociation of phosphate (from the rise in urinary pH) and
augmentation of calcium phosphate saturation [25].
ure.
The fundamental deficit leading to uric acid lithiasis is low
urinary pH [7]. The consequent fall in uric acid dissociation
reduces uric acid solubility, leading to the urinary
supersaturation and crystallization of uric acid. Since potas-
sium citrate provides an alkali load [271, its characteristic
physiological response is a rise in urinary pH. At an average
dose of 60 mEq/day, urinary pH was usually maintained above
6 hut less than 7. Thus, normal dissociation ot' uric acid was
achieved, hut dangers of calcium phosphate precipitation from
an excessive alkalinization was avoided [3. 4]. Before treat-
ment, the mean urinary concentration of undissociated uric acid
of 132 mg/liter exceeded the soluhility of uric acid of 96 mg/liter
[7]. Following potassium citrate treatment, urinary concentra-
tion of undissociated uric acid decreased below the solubility
limit, largely due to a decline in total urinary excretion of
undissociated uric acid, and partly to an increase in urine
volume. Therefore, inhibition of uric acid stone formation was
expected, since the urinary environment became undersatu-
rated with respect to uric acid.
Potassium citrate treatment probably created an urinary
environment less conducive to the crystallization of calcium
oxalate as well. As shown before in patients with hypocitraturic
calcium oxalate nephrolithiasis, this treatment reduced the
urinary saturation of calcium oxalate by promoting calcium
complcxation to citrate and phosphate and reducing ionic
calcium content [5, 8]. The inhibitor activity against the crys-
tallization of calcium oxalatc and calcium phosphate would he
expected to be increased I'rom the rise in urinary citrate and pH
[28, 29]. Thus, the propensity for the spontaneous precipitation
of calcium oxalate in urine, as measured by the permissible
increment, declined during potassium citrate treatment. The
results could explain the prevention of calcium stone formation
by potassium citrate therapy in 12 of 17 patients with uric acid
lithiasis who had this complication.
*
*
*
-.
I I
It should be emphasized that calcium stones may form in
—. patients with uric acid lithiasis even when they do not take
alkali therapy [71. This mixed stone formation could be cx-
plained by transient rises in urinary pH (such as following
ingestion of a diet high in alkaline ash content), or by direct
•
______
involvement of undissociated uric acid in eliciting calcium
oxalate crystallization 124, 26]. Moreover, it is recognized that
not all patients with uric acid lithiasis may develop the compli-
cation of calcium stones during sodium alkali therapy. Case 5,
for example, had an apparent reduced stone formation rate
when treatment with alkali containing sodium was imposed.
Noteworthy is the finding suggesting that the institution of
—. . potassium citrate therapy not only prevents formation of uric
A acid stones, but averts the complication of calcium stones,
A which may be attendant with sodium alkali therapy. The five
patients with uric acid stones, who formed calcium stones
3 2 1 0 + 1 2 -3 4 5 +6 during sodium alkali therapy, stopped forming stones of either
Years prior Years on K citrate uric acid or calcium salt altogether during potassium alkali
to therapy therapy. Among 18 patients with uric acid lithiasis undergoing
long—term trial, only one stone was formed by the entire group
during a mean treatment period of 2.27 years, yielding a
remission rate of 94.1% and a reduction in group stone forma-
tion rate of 99.2%.
The above favorable therapeutic response could he explained
by the accompanying physiological and physicochemical pie-
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It is expected that other soluble alkaline salts of potassium
would exert a qualitatively similar action as potassium citrate.
However, potassium citrate may be advantageous because of
its potential for prolonging and enhancing the citraturic re-
sponse, Moreover, the physiological action of potassium citrate
with respect to enhancement of citrate excretion is expected to
last longer than that of more readily available alkali, because of
the delay in the conversion of citrate to alkali.
Gouty diathesis probably represented the metabolic back-
ground for uric acid lithiasis in four patients from the case
reports, and in three patients undergoing long—term clinical
trial. Although only two patients had gouty arthritis, all seven
patients had gouty diathesis, since they had hyperuricemia, low
urinary pH and uric acid lithiasis, without apparent cause for
high serum uric acid or low urinary pH. However, the exact
cause for the low urinary pH probably responsible for uric acid
stone formation in the remaining 14 patients undergoing
long—term trial is unknown. Although Coe reported lower
urinary pH in patients with uric acid calculi than in those with
mixed stones (uric acid and calcium) [71, we were unable to
confirm this finding.
In conclusion, this study provides physiological and
physicochemical rationale for the use of potassium citrate in the
management of uric acid lithiasis occurring alone or with
calcium nephrolithiasis, This treatment creates an urinary envi-
ronment less conducive to the crystallization of uric acid by
increasing urinary pH and reducing the amount of undissociated
uric acid. It inhibits urinary crystallization of calcium oxalate
by reducing urinary saturation and augmenting inhibitor activity
owing to the rise in urinary citrate and pH. The clinical
correlation is provided by virtual elimination of the formation of
both types of stones during long—term treatment.
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